KZR

Kezar Life Sciences, Inc.

1.02 USD
-0.03 (-2.86%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kezar Life Sciences, Inc. stock is up 3.03% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 March’s closed higher than February.

About Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc. engages in the discovery and development of novel small molecule therapeutics. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis.